Claims
- 1) A compound of formula I
- 2) A compound of claim 1 wherein R1 is hydrogen.
- 3) A compound of claim 1 wherein R2, R3 and R4 are independently selected from hydrogen, halogen, and cyano.
- 4) A compound of claim 1 wherein R5 is hydrogen or lower alkyl.
- 5) A compound of claim 1 wherein X is CR6.
- 6) A compound of claim 5 wherein R6 is hydrogen, halogen or cyano.
- 7) A compound of claim 1 in which R1 is attached to the 6-position of the 1,4-dioxino[2,3-b]pyridine and is hydrogen, hydroxy, halo, cyano, trifluoromethyl, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkyl of one to six carbon atoms or alkoxy of one to six carbon atoms; R2, R3 and R4 are independently selected from hydrogen, halo, cyano, alkyl of one to six carbon atoms, and alkoxy of one to six carbon atoms; n is an integer 0 or 1; or a pharmaceutically acceptable salt thereof.
- 8) A compound of claim 1 in which R1 is attached to the 6-position of the 1,4-dioxino[2,3-b]pyridine and is hydrogen, hydroxy or alkoxy of one to six carbon atoms, R2, R3 and R4 are independently selected from hydrogen, halo and cyano, R5 is hydrogen, X is CR6, n is 0, and the dotted line represents a double bond; or a pharmaceutically acceptable salt thereof.
- 9) A compound of claim 7 wherein R6 is hydrogen, halo or cyano.
- 10) The compound of claim 1 which 3-{[4-(1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl}-2,3-dihydro[1,4]dioxino[2,3-b]pyridine or a pharmaceutically acceptable salt thereof.
- 11) The compound of claim 1 which is 3-{[4-(S-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methy}-2,3-dihydro{1,4]dioxino[2,3-b]pyridine or a pharmaceutically acceptable salt thereof.
- 12) The compound of claim 1 which is 3-{1-[2,3-dihydro[1,4]dioxino[2,3-b]pyridin-3-ylmethyl]-1,2,3,6-tetrahydro-4-pyridinyl}-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
- 13) The compound of claim 1 which is 3-{[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]methyl}2,3-dihydro[1,4]dioxino[2,3-b]pyridine or a pharmaceutically acceptable salt thereof.
- 14) A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, and sexual dysfunction which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I
- 15) The method of claim 13 wherein wherein th condition is depression.
- 16) The method of claim 13 wherein the condition is obsessive compulsive disorder, panic attacks, generalized anxiety disorder or social anxiety disorder.
- 17) The method of claim 13 wherein the subject is a human.
- 18) A pharmaceutical composition comprising a compound of formula I
Parent Case Info
[0001] This application claims priority from co-pending provisional application serial No. 60/286,301, filed on Apr. 25, 2001, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60286301 |
Apr 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10127923 |
Apr 2002 |
US |
Child |
10661182 |
Sep 2003 |
US |